Quanterix (QTRX)
(Real Time Quote from BATS)
$13.45 USD
+0.03 (0.22%)
Updated Aug 6, 2024 02:32 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
QTRX 13.45 +0.03(0.22%)
Will QTRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for QTRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QTRX
BellRing Brands (BRBR) Q3 Earnings and Revenues Top Estimates
Ayr Wellness Inc. (AYRWF) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
QTRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Quanterix Corporation (QTRX) to Report a Decline in Earnings: What to Look Out for
Wall Street Analysts Believe Quanterix (QTRX) Could Rally 67.66%: Here's is How to Trade
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
Other News for QTRX
Quanterix To Report Second Quarter 2024 Financial Results
What's Driving Avanos Medical Inc's Surprising 34% Stock Rally?
Buy Recommendation for Quanterix Amid Strong Prospects in Alzheimer’s Diagnostics
Quanterix Presents Data Demonstrating Successful Multi-Marker Approach for Alzheimer?s Disease Detection that is More Effective than Standalone Plasma p-Tau 217
Quanterix presents new Alzheimer's disease data at AAIC